Hua Jiang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1594490/publications.pdf

Version: 2024-02-01

36 papers	1,893 citations	279798 23 h-index	361022 35 g-index
37 all docs	37 docs citations	37 times ranked	2362 citing authors

#	Article	IF	Citations
1	Chimeric anti-GPC3 sFv-CD3Îµ receptor-modified T cells with IL7 co-expression for the treatment of solid tumors. Molecular Therapy - Oncolytics, 2022, 25, 160-173.	4.4	4
2	Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen. Briefings in Bioinformatics, 2021, 22, .	6.5	16
3	Olaparib Suppresses MDSC Recruitment via SDF1Î±/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. Molecular Therapy, 2021, 29, 60-74.	8.2	51
4	Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors. Critical Reviews in Immunology, 2021, 41, 1-12.	0.5	6
5	Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion. Clinical Cancer Research, 2020, 26, 5494-5505.	7.0	79
6	Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clinical Cancer Research, 2020, 26, 3979-3989.	7.0	184
7	An IL-4/21 Inverted Cytokine Receptor Improving CAR-T Cell Potency in Immunosuppressive Solid-Tumor Microenvironment. Frontiers in Immunology, 2019, 10, 1691.	4.8	70
8	Growth suppression of colorectal cancer expressing S492R EGFR by monoclonal antibody CH12. Frontiers of Medicine, 2019, 13, 83-93.	3.4	2
9	Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3â€“Targeted Chimeric Antigen Receptorâ€“Engineered T Cells in Hepatocellular Carcinoma. Journal of Immunology, 2019, 203, 198-207.	0.8	95
10	Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma. Molecular Therapy, 2019, 27, 1483-1494.	8.2	100
11	Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells. Frontiers in Oncology, 2019, 9, 241.	2.8	54
12	Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice. Biomedicine and Pharmacotherapy, 2019, 113, 108734.	5.6	34
13	Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells. Frontiers in Oncology, 2019, 9, 1448.	2.8	25
14	Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. Journal of the National Cancer Institute, 2019, 111, 409-418.	6.3	129
15	Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma. Molecular Therapy, 2018, 26, 366-378.	8.2	124
16	Species-Specific Involvement of Integrin Î±IIbÎ²3 in a Monoclonal Antibody CH12 Triggers Off-Target Thrombocytopenia in Cynomolgus Monkeys. Molecular Therapy, 2018, 26, 1457-1470.	8.2	4
17	The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III. Cellular Physiology and Biochemistry, 2018, 46, 226-237.	1.6	10
18	Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma. Frontiers in Pharmacology, 2018, 9, 1118.	3.5	126

#	Article	IF	Citations
19	Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell. Cancer Immunology Research, 2018, 6, 1314-1326.	3.4	37
20	Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1â€“CH3 fusion protein. Cancer Immunology, Immunotherapy, 2018, 67, 1621-1634.	4.2	46
21	Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2017, 66, 475-489.	4.2	80
22	Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells. Protein and Cell, 2017, 8, 926-931.	11.0	22
23	A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T Cells. Molecular Therapy, 2017, 25, 2270-2279.	8.2	9
24	EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer. Molecular Cancer, 2017, 16, 127.	19.2	63
25	A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC).. Journal of Clinical Oncology, 2017, 35, 3049-3049.	1.6	61
26	Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager. Oncotarget, 2017, 8, 52866-52876.	1.8	38
27	EGFR regulates iron homeostasis to promote cancer growth through redistribution of transferrin receptor 1. Cancer Letters, 2016, 381, 331-340.	7.2	58
28	Weak binding to E3 ubiquitin ligase câ€Cbl increases EGFRvA protein stability. FEBS Letters, 2016, 590, 1345-1353.	2.8	1
29	Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. Oncotarget, 2016, 7, 2496-2507.	1.8	31
30	Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTENâ^' glioblastoma in vivo. Oncotarget, 2016, 7, 24752-24765.	1.8	13
31	Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12. Oncotarget, 2015, 6, 38840-38853.	1.8	6
32	Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 6418-6428.	7.0	233
33	The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Cancer Letters, 2014, 342, 113-120.	7.2	15
34	EGFRvIII Mediates Hepatocellular Carcinoma Cell Invasion by Promoting S100 Calcium Binding Protein A11 Expression. PLoS ONE, 2013, 8, e83332.	2.5	26
35	Growth Suppression of Human Hepatocellular Carcinoma Xenografts by a Monoclonal Antibody CH12 Directed to Epidermal Growth Factor Receptor Variant III. Journal of Biological Chemistry, 2011, 286, 5913-5920.	3.4	41
36	Differential Expression of VEGF and Its Receptors in the Primary Cells of Various Risk Classified Acute Lymphoblastic Leukemia Patients.. Blood, 2004, 104, 4446-4446.	1.4	0